Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA · NASDAQ Global Select
-$0.10 today
Vol 2.20M · Avg 2.02M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:NMRA · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$222.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.33, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $5.0M | $0 -100.0% | $668.0K | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$5.0M | $0 +100.0% | -$668.0K | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $176.1M -12.4% | $200.9M +40.8% | $142.7M +36.2% | $104.7M -50.8% | $212.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $60.1M -3.9% | $62.5M +39.6% | $44.8M +44.0% | $31.1M +26.8% | $24.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $236.2M -10.4% | $263.5M +40.5% | $187.5M +38.0% | $135.9M -42.7% | $237.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $208.0K -67.0% | $631.0K -5.5% | $668.0K +12.5% | $594.0K +10.4% | $538.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$233.4M +4.0% | -$243.0M -3.4% | -$235.0M -80.3% | -$130.3M +45.0% | -$236.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$241.2M +8.5% | -$263.5M -40.0% | -$188.2M -38.5% | -$135.9M +42.7% | -$237.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $8.3M -58.1% | $19.9M +20.0% | $16.6M +264.2% | $4.6M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.2M | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $4.4M -78.1% | $19.9M +141.8% | -$47.5M -1055.8% | $5.0M +45045.5% | $11.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$236.8M +2.8% | -$243.6M -3.4% | -$235.7M -80.0% | -$130.9M +44.8% | -$237.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $130.0K -27.0% | $178.0K -33.6% | $268.0K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$236.9M +2.8% | -$243.8M -3.3% | -$235.9M -80.2% | -$130.9M +44.8% | -$237.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +5.2% | -$2 -2.7% | -$1 -73.3% | -$1 +44.9% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +5.2% | -$2 -2.7% | -$1 -73.3% | -$1 +44.9% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $163.4M +2.5% | $159.4M +0.3% | $158.8M +4.5% | $151.9M +0.0% | $151.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $163.4M +2.5% | $159.4M +0.3% | $158.8M +4.5% | $151.9M +0.0% | $151.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.84B
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$890.35M
Omeros Corporation
NASDAQ:OMER
$746.91M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$501.06M
Prothena Corporation plc
NASDAQ:PRTA
$463.33M
Autolus Therapeutics plc
NASDAQ:AUTL
$409.86M
Bicycle Therapeutics plc
NASDAQ:BCYC
$276.54M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$194.80M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NMRA generate?
Neumora Therapeutics, Inc. Common Stock (NMRA) reported $0.00 of revenue in fiscal 2025.
Is NMRA profitable?
Neumora Therapeutics, Inc. Common Stock (NMRA) reported -$236,928,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.